Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F-18-fluorothymidine - National Cancer Institute

Drug Profile

F-18-fluorothymidine - National Cancer Institute

Alternative Names: 18-F-fluorothymidine; 18F-FLT - National Cancer Institute; 18F-fluorothymidine - National Cancer Institute; 3'-deoxy-3'-[18F] Fluorothymidine PET/CT scanning - National Cancer Institute; F-18-FLT; Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) - National Cancer Institute

Latest Information Update: 25 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); Radboud-University-Nijmegen-Medical-Centre; University of Washington
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Glioma
  • No development reported Cancer metastases

Most Recent Events

  • 25 Aug 2015 Clinical development for Glioma (diagnosis) is ongoing in the USA
  • 25 Aug 2015 F-18-fluorothymidine is still in phase II trials for Breast cancer (Diagnosis) in the USA
  • 03 Feb 2014 Case Comprehensive Cancer Center and National Cancer Institute plan a clinical trial for Solid tumours (diagnosis) in USA (NCT02055586)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top